Walvax Biotechnology Co., Ltd. (SHE:300142)
10.00
-0.64 (-6.02%)
Nov 20, 2026, 3:04 PM CST
Walvax Biotechnology Revenue
Walvax Biotechnology had revenue of 312.70M CNY in the quarter ending September 30, 2026, a decrease of -44.61%. This brings the company's total for the last twelve months to 1.85B, down -23.03% year-over-year. In the year 2025, Walvax Biotechnology had annual revenue of 2.42B, down -14.29%. That makes Walvax Biotechnology the 15,132nd largest company in the world by revenue and 2,720th in China.
Revenue (ttm)
1.85B
Revenue Growth
-23.03%
P/S Ratio
8.75
Revenue / Employee
932.03K
Employees
1,981
Market Cap
15.99B
Revenue by Geography
- Eastern China 679.27M 28.1%
- Overseas Region 522.04M 21.6%
- South China Region 400.71M 16.6%
- Southwest Northwest Region 346.88M 14.3%
- Central China Region 256.31M 10.6%
- Northeast and North China 213.01M 8.8%
Fiscal year ended Dec 31, 2025 See the full Walvax Biotechnology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.42B | -403.21M | -14.29% |
| Dec 31, 2024 | 2.82B | -1.29B | -31.41% |
| Dec 31, 2023 | 4.11B | -972.67M | -19.12% |
| Jan 1, 2023 | 5.09B | 1.62B | 46.89% |
| Jan 1, 2022 | 3.46B | 523.81M | 17.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.